Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul N Durrington

Showing results (21-30 of 106) with videos related to

Pageof 11
Sort By:
Clinical Chemistry and Laboratory Medicine|July 8, 2008
Use of the TLX ultracentrifuge for the isolation of different density lipoproteins and effects of freeze/thawing of human plasma before ultracentrifugationValentine Charlton-Menys, Jelena Chobotova, Paul N Durrington
Current Opinion in Lipidology|August 2, 2002
The paraoxonase gene family and coronary heart diseaseBharti Mackness, Paul N Durrington, Michael I Mackness
Clinical Chemistry|January 21, 2006
Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrateValentine Charlton-Menys, Yifen Liu, Paul N Durrington
Current Opinion in Lipidology|July 1, 2014
The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapyHandrean Soran, Jonathan D Schofield, Paul N Durrington
Atherosclerosis. Supplements|February 8, 2003
Paraoxonase and coronary heart diseaseMichael I Mackness, Bharti Mackness, Paul N Durrington
Frontiers in Pharmacology|November 4, 2015
Antioxidant properties of HDLHandrean Soran, Jonathan D Schofield, Paul N Durrington
Current Opinion in Lipidology|May 11, 2018
Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targetsHandrean Soran, Jan Hoong Ho, Paul N Durrington
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 3, 2004
The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic interventionMichael I Mackness, Paul N Durrington, Bharti Mackness
European Heart Journal|August 6, 2015
Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatmentHandrean Soran, Jonathan D Schofield, Paul N Durrington
Current Opinion in Lipidology|June 27, 2012
HDL functionalityHandrean Soran, Salam Hama, Rahul Yadav, et al.
Pageof 11

Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
Clinical Chemistry and Laboratory Medicine|July 8, 2008
Use of the TLX ultracentrifuge for the isolation of different density lipoproteins and effects of freeze/thawing of human plasma before ultracentrifugationValentine Charlton-Menys, Jelena Chobotova, Paul N Durrington
Current Opinion in Lipidology|August 2, 2002
The paraoxonase gene family and coronary heart diseaseBharti Mackness, Paul N Durrington, Michael I Mackness
Clinical Chemistry|January 21, 2006
Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrateValentine Charlton-Menys, Yifen Liu, Paul N Durrington
Current Opinion in Lipidology|July 1, 2014
The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapyHandrean Soran, Jonathan D Schofield, Paul N Durrington
Atherosclerosis. Supplements|February 8, 2003
Paraoxonase and coronary heart diseaseMichael I Mackness, Bharti Mackness, Paul N Durrington
Frontiers in Pharmacology|November 4, 2015
Antioxidant properties of HDLHandrean Soran, Jonathan D Schofield, Paul N Durrington
Current Opinion in Lipidology|May 11, 2018
Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targetsHandrean Soran, Jan Hoong Ho, Paul N Durrington
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 3, 2004
The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic interventionMichael I Mackness, Paul N Durrington, Bharti Mackness
European Heart Journal|August 6, 2015
Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatmentHandrean Soran, Jonathan D Schofield, Paul N Durrington
Current Opinion in Lipidology|June 27, 2012
HDL functionalityHandrean Soran, Salam Hama, Rahul Yadav, et al.
Pageof 11